Jeff Fairman's most recent trade in Vaxcyte Inc was a trade of 15,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 30, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | Jeff Fairman | VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 26 Oct 2022 | 10,000 | 286,227 | - | 40 | 400,000 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 11 Oct 2022 | 5,000 | 296,227 | - | 25.5 | 127,500 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 26.54 per share. | 02 Sep 2022 | 4,664 | 301,563 | - | 26.5 | 123,774 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.38 per share. | 02 Sep 2022 | 519 | 17,143 | - | 26.4 | 13,691 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 27.14 per share. | 02 Sep 2022 | 336 | 301,227 | - | 27.1 | 9,118 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 04 Aug 2022 | 10,000 | 311,227 | - | 25.5 | 255,000 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 04 Aug 2022 | 5,000 | 306,227 | - | 25.7 | 128,508 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 20 May 2022 | 4,112 | 321,227 | - | 25.5 | 104,856 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.80 per share. | 05 May 2022 | 888 | 325,339 | - | 25.8 | 22,914 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.59 per share. | 05 Apr 2022 | 5,000 | 326,227 | - | 25.6 | 127,950 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.50 per share. | 11 Mar 2022 | 10,000 | 331,227 | - | 25.5 | 255,000 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2021 | 4,750 | 53,345 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 27 Dec 2021 | 4,750 | 10,910 | - | 1.8 | 8,503 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 23.58 per share. | 27 Dec 2021 | 4,575 | 6,335 | - | 23.6 | 107,879 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 24.08 per share. | 27 Dec 2021 | 175 | 6,160 | - | 24.1 | 4,214 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 16 Dec 2021 | 4,619 | 6,160 | - | 22.5 | 103,928 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2021 | 4,619 | 58,095 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 16 Dec 2021 | 4,619 | 10,779 | - | 1.8 | 8,268 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 09 Dec 2021 | 131 | 6,291 | - | 1.8 | 234 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2021 | 131 | 62,714 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 09 Dec 2021 | 131 | 6,160 | - | 22.5 | 2,948 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 26 Oct 2021 | 4,750 | 5,144 | - | 22.7 | 107,778 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Oct 2021 | 4,750 | 62,845 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 26 Oct 2021 | 4,750 | 9,894 | - | 1.8 | 8,503 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Sep 2021 | 4,750 | 67,595 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 27 Sep 2021 | 4,750 | 9,894 | - | 1.8 | 8,503 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 26.16 per share. | 27 Sep 2021 | 4,611 | 5,283 | - | 26.2 | 120,624 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 26.47 per share. | 27 Sep 2021 | 139 | 5,144 | - | 26.5 | 3,679 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 4,750 | 72,345 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.79 per share. | 26 Aug 2021 | 4,750 | 9,894 | - | 1.8 | 8,503 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 25.70 per share. | 26 Aug 2021 | 3,218 | 5,144 | - | 25.7 | 82,703 | Common Stock |
| Vaxcyte Inc | Jeff Fairman | VP, Research | Sale of securities on an exchange or to another person at price $ 24.70 per share. | 26 Aug 2021 | 1,532 | 8,362 | - | 24.7 | 37,840 | Common Stock |